海外招待講演者
Peters Solange
Professor, Oncology Department, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland
GL1
Patrick Forde
Professor, Bloomberg-Kimmel Institute for Cancer Immunotherapy, Johns Hopkins University, USA
SY1: Looking back on2022/2023 dramatic change in perioperative treatment 2022/2023
Heather Wakelee
Professor, Stanford University, USA
SY1 : Looking back on2022/2023 dramatic change in perioperative treatment 2022/2023
Roy S. Herbst
Professor, Yale School of Medicine, USA
SY2: New horizon of combination therapy of immunocheckpoint inhibitors
Hisataka Kobayashi
Professor, National Cancer Institute, NIH
SY3 : Front line of drug discovery in lung cancer
Maximilian Diehn
Professor, Stanford University, USA
SY7 : Will MRD change lung cancer treatments?
James M Isbell
Professor, Memorial Sloan Kettering Cancer Center, USA
SY9 : What is global standard of sublobar resection ?: Current situation and issues
Jay M. Lee
Professor, Division of Thoracic Surgery, University of California at Los Angeles (UCLA), United States of America
WS14 : Front line of perioperative treatment
Paul van Schil
Professor, Department of Thoracic and Vascular Surgery, Antwerp University Hospital, Belgium
DB1 : What is an optimal strategy for clinical stage IIIA-N2 NSCLC